针对肺部疾病的基于介质素-10的疗法取得了进展:重点是针对性肺部输送系统
Weikun Tian1, Xu Wang1, Jia Zeng2
1School of Clinical Medicine, Shandong Second Medical University, Weifang, China.
Frontiers in immunology
|November 28, 2025
概括
介质素-10 (IL-10) 显示出治疗肺炎的前景. 新的输送系统旨在提高其有效性,并减少急性肺损伤和喘等疾病的副作用.
科学领域:
- 免疫学 免疫学 免疫学
- 肺部医学 肺部医学
- 生物技术是生物技术.
背景情况:
- 介素-10 (IL-10) 是一种关键的抗炎细胞因子,调节免疫反应.
- IL-10对ALI,ARDS,喘和纤维化等肺炎性疾病具有治疗潜力.
- 目前IL-10的临床应用受到生物可用性差,半衰期短和全身毒性的限制.
研究的目的:
- 审查目前用于肺部疾病的IL-10输送系统.
- 突出优化IL-10输送的策略,以提高治疗疗效和肺向.
- 讨论基于IL-10的疗法临床转化所面临的挑战和机遇.
主要方法:
- 对鼻内注射,雾化吸入,重组蛋白,人工干细胞和纳米颗粒/凝输送系统的审查.
- 将IL-10疗法分类为延长外源IL-10半衰期和增强内源IL-10分泌.
- 对IL-10融合蛋白,纳米粒子/水凝系统,表达等离子体和腺病毒的分析.
主要成果:
- 肺部向输送方法增加了肺部药物积累和持续释放,最大限度地降低了全身毒性.
- 策略包括开发IL-10融合蛋白,纳米粒子和水凝输送系统以及IL-10表达载体.
- 有针对性的输送提供了IL-10活动的精确空间和时间调节.
结论:
- IL-10输送系统面临挑战,包括狭窄的治疗窗口和患者异质性.
- 新兴的有针对性的输送策略对于克服局限性和实现精确的IL-10调制至关重要.
- 优化这些系统对于促进肺部疾病中IL-10的临床转化至关重要.
相关概念视频
Drugs Used in Lower Respiratory Disorders: Overview
1.0K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.0K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
Chronic Obstructive Pulmonary Disease-V: Management
3.1K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.1K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K


